In last trading session, Denali Therapeutics Inc (NASDAQ:DNLI) saw 1.36 million shares changing hands with its beta currently measuring 1.45. Company’s recent per share price level of $15.49 trading at $0.62 or 4.17% at ring of the bell on the day assigns it a market valuation of $2.25B. That closing price of DNLI’s stock is at a discount of -115.17% from its 52-week high price of $33.33 and is indicating a premium of 31.76% from its 52-week low price of $10.57. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.42 million shares which gives us an average trading volume of 1.30 million if we extend that period to 3-months.
For Denali Therapeutics Inc (DNLI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.05. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Denali Therapeutics Inc (NASDAQ:DNLI) trade information
Upright in the green during last session for gaining 4.17%, in the last five days DNLI remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $15.49 price level, adding 1.15% to its value on the day. Denali Therapeutics Inc’s shares saw a change of -23.99% in year-to-date performance and have moved 23.43% in past 5-day. Denali Therapeutics Inc (NASDAQ:DNLI) showed a performance of 9.70% in past 30-days. Number of shares sold short was 11.44 million shares which calculate 7.98 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 38.5 to the stock, which implies a rise of 59.77% to its current value. Analysts have been projecting 32 as a low price target for the stock while placing it at a high target of 45. It follows that stock’s current price would drop -106.58% in reaching the projected high whereas dropping to the targeted low would mean a loss of -106.58% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -4.46% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -11.64% while estimates for its earnings growth in next 5 years are of 8.81%.
Denali Therapeutics Inc (NASDAQ:DNLI)’s Major holders
Insiders are in possession of 9.56% of company’s total shares while institution are holding 90.82 percent of that, with stock having share float percentage of 100.42%. Investors also watch the number of corporate investors in a company very closely, which is 90.82% institutions for Denali Therapeutics Inc that are currently holding shares of the company. BAILLIE GIFFORD & CO is the top institutional holder at DNLI for having 13.76 million shares of worth $319.59 million. And as of 2024-06-30, it was holding 8.1523 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 13.17 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.8034 of outstanding shares, having a total worth of $305.91 million.
On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 7.97 shares of worth $123.48 million or 5.49% of the total outstanding shares. The later fund manager was in possession of 3.72 shares on Dec 31, 2024 , making its stake of worth around $57.64 million in the company or a holder of 2.56% of company’s stock.
